Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Longer-Term Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study

NCT03292484 is registered in ClinicalTrials.gov with Aimmune Therapeutics, Inc. as lead sponsor.

NCT NCT03292484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03292484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Longer-Term Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study
Lead sponsor
Aimmune Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 2, 2017
Completion date
April 27, 2023
Enrollment
911 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy